At the forefront of scientific innovation, driven by a vision that pushes beyond the boundaries of modern biotechnology, Novopharma was founded in April 2006 in the United States marking the beginning of a quiet yet powerful revolution in the fields of health, genetics, and dermocosmetics. Established by the renowned scientist Dr. Micke English, a leading figure in applied biochemistry, the company was born from years of research, clinical expertise, and an unwavering obsession with understanding and transforming the deepest codes of the human body. Rather than merely addressing symptoms, Novopharma’s philosophy is rooted in intervening at the source: genetics itself. From this foundation, the company has developed advanced product lines designed to positively impact complex conditions such as eating disorders, nutritional deficiencies, alopecia, and a wide range of genetic imbalances delivering solutions that do not just improve lives, but redefine them.

Over time, Novopharma identified dermocosmetics as its most powerful niche, establishing itself as a leader in the development of formulations that merge science, aesthetics, and clinically proven results. Its business model has been strategically structured: in the United States, its products are distributed exclusively through major pharmacy chains, reinforcing a premium positioning and consumer trust; across Latin America, the company has built a strong network of commercial representatives; while in Europe, Novopharma is firmly established within a select group of hospitals and specialized pharmacies, elevating its international prestige.

Supported by a state-of-the-art research center equipped with cutting-edge technology, and operating under strict international standards such as BMA guidelines, ISO certifications, and FDA regulations, Novopharma ensures safety, ethics, and excellence at every level. The company also stands out for its commitment to responsible innovation: its products are not tested on animals and are rigorously dermatologically tested, guaranteeing effective, predictable results aligned with the expectations of today’s sophisticated consumers. At the core of this scientific ecosystem remains Dr. English, who continues to lead research and development, ensuring that every innovation represents a true leap forward in the industry.

Meanwhile, the company’s global vision and strategic expansion are led by Jessika English, who oversees international operations, logistics, and administration. Under her leadership, Novopharma not only optimizes its global structure but also embraces a powerful philosophy: to always stay one step ahead of the future. This mindset drives the company to create comprehensive solutions that bridge science with human well-being, positioning Novopharma not as a follower of trends—but as a creator of them. In essence, Novopharma is more than a pharmaceutical company; it is a bridge between genetics, innovation, and the limitless potential of human transformation.